T-vant: A Novel Adjuvant for Transformative Vaccines

Inducing Immunity at the Source of Infection

Download One-Pager Download Slide Deck

Inducing Immunity at the Source of Infection

T-Vant is a potent adjuvant developed by Tulane scientists. This isolated lipid nanoparticle can stimulate not only the B-Cells and CD4+ T-Cells usually associated with vaccine protection, but also stimulates a potent CD8+ T-cell response. This new technology is suitable for use with any microbe or antigen and has been tested in multiple virus and bacterial challenge models.

Researchers

Why T-vant?

Robust Multi-Arm Immune Boost

Activates humoral, cellular and mucosal responses, delivering broader, longer-lasting protection.

Universal Vaccine Compatibility

Works as a simple admix with protein, peptide, inactivated, and other antigens, reducing need for reformulation.

Dose-Sparing & Single-Shot Potential

Enhances neutralizing titers ≥10-fold and prolongs memory B- and T-cell responses, enabling lower antigen doses or single-dose regimens.

Clean Safety & Low Reactogenicity

Demonstrates excellent tolerability in mice, rabbits, non-human primates, and the MIMIC human surrogate system.

Mucosal & Needle-Free Delivery

Retains full adjuvant potency when given intranasally or orally, supporting needle-free mass-vaccination.

Following uptake of T-vant and its antigen payload, T-vant activates immunity across all arms of the immune system; in particular, strong immunity is induced at mucosal tissues, often the site of initial infection.

T-vant provides antigen-agnostic protection against a broad spectrum of respiratory, gastrointestinal, and other infectious diseases.

Publications

A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis View
Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization View
An Outer Membrane Vesicle-Adjuvanted Oral Vaccine Protects Against Lethal, Oral Salmonella Infection View
Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses View

Other resources

BIO from the Bayou Podcast: Unveiling the T-vant Adjuvant with Key Opinion Leaders Lisa Morici and James McLachlan View
Title Country Date of Application Serial / ID Number Additional Notes
Bacterial Outer-Membrane Vesicles Derived Adjuvants US 10/09/2020 11,534,486
Bacterial Outer-Membrane Vesicles Derived Adjuvants PCT 04/10/2019 PCT/US2019/026769 Nationalized to "CA, IN, AU. KP. EPO. CN

Explore a Partnership

Flexible collaboration models available — Sponsored Research, Co-Development, Licensing.

For inquiries, contact:
Alexis Ducote, PhD
Business Development Associate
aducote@tulane.edu
337.540.4025

X

Schedule a call

Set up a meeting with one of our team members by using the Calendly integration below.

Is it urgent? Call us:

James Zanewicz (+1 504.919.3800),

Alexis Ducote (+1 337.540.4025),

Carolyn Scofield (+1 504.881.4542).